Inge Marie Svane has 25 years of research experience in cancer immunology and immunotherapy and holds a PhD in Basic Cancer Immunology and a Professorship in Clinical Cancer Immunotherapy. She has pioneered the field of cancer immunotherapy in Denmark and has built up the Cenre for Cancer Immunotherapy (CCIT), a translational research centre, in to a leading European centre. Her focus of expertise is T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation.
Dr. Svane currently holds the following positions: Consultant, Dept. of Oncology, Copenhagen University Hospital, Herlev; Professor, Copenhagen University, Clinical Cancer Immune Therapy and Director, CCIT, Copenhagen University Hospital. She is also Head of oncologic treatment of disseminated melanoma in Eastern Denmark; Head of Immunotherapy, Dept. of Oncology, and Head of Unit for GMP immune cell production, Copenhagen University Hospital, Herlev and Head of the PhD education Programme in Clinical Cancer Research, Copenhagen University.
Since 2001 she has initiated 15 phase I, II and III immunotherapeutic trials as sponsor. She is national/principal investigator of numerous international clinical trials in collaboration with pharmaceutical industry primarily within the area of immunotherapy.
Dr. Svane has an extensive network of scientists and clinicians nationally and internationally and frequently speaks at national and international meetings, courses and conferences.
She is a key opinion leader on cancer immunotherapy acknowledging the importance of communication to the public, patient associations and politicians. She actively supports the European Cancer Patient Coalition as scientific committee member in the Immuno-Oncology Academy.
Dr. Svane is an ESMO Congress session speaker and an ESMO clinical research fellow host. She is also a member of the European Melanoma Group, EORTC, and of the Danish Melanoma Group heading national treatment guidelines.
Dr. Svane is author/co-author of more than 140 scientific publications including papers in Clinical Cancer Research, Cancer Research, Blood, Nature Immunology, Nature Biotechnology, Lancet Oncology, Immunology, Journal of Translational Medicine, PLOS ONE, Oncoimmunology, amongst others.
ESMO 2017 Congress
"The Immunotherapy of Cancer Track will show how immunotherapy is significantly improving survival for an increasing number of cancer patients, pointing out the path forward in oncology."
Inge Marie Svane
Inge Marie Svane was the Immunotherapy of Cancer Track Chair of the ESMO 2017 Congress, which took place in Madrid, Spain (8-12 September 2017).